First, Dazheng Biology and Pfizer China have reached a partnership to accelerate the commercialization process of biased GLP-1.

On February 24, Pioneer Biotech and Pfizer (PFE.US) China announced that the two parties have reached a strategic commercialization cooperation agreement for the next-generation biased GLP-1 receptor agonist, Enooglutide Injection. Under the agreement, Pfizer will obtain exclusive commercialization rights for the product in mainland China, marking its first step in the strategic layout of the global metabolic field in China; at the same time, Pioneer Biotech will be the license holder for the approved product, responsible for the development, registration, production, and supply of the licensed product. Pioneer Biotech will be entitled to receive a total payment of up to $495 million from Pfizer, including upfront payments, registration, and sales milestone payments.

Enooglutide is a new generation cAMP-biased GLP-1 receptor agonist independently developed by Pioneer Biotech, providing more precise treatment options for patients with type 2 diabetes and long-term weight management. With its unique biased mechanism, Enooglutide injection has demonstrated excellent efficacy and safety in multiple clinical studies. In the Chinese population, the adjusted average weight loss in the placebo-controlled group was 15.1%, with 92.8% of patients achieving clinically meaningful weight loss, and over 80% of patients reaching blood sugar control (HbA1c<7.0%). Enooglutide injection was approved for marketing by the National Medical Products Administration (NMPA) in January 2026 for the treatment of adult type 2 diabetes, and its marketing authorization application for long-term weight management in adults has been accepted by the NMPA.